Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Elite Pharmaceuticals ( (ELTP) ) has provided an update.
Elite Pharmaceuticals has secured FDA approval for a generic version of Vyvanse®, a widely-used treatment for ADHD, marking a significant opportunity in a market valued at $4.3 billion. With this approval, Elite is set to market the medication in various strengths under its Elite Laboratories brand, potentially boosting its presence in the pharmaceutical industry.
For an in-depth examination of ELTP stock, go to TipRanks’ Stock Analysis page.